So far, only wealthy large investors and institutional groups such as family offices, hedge funds and private equity companies have been able to invest in the newly emerging asset class of psychedelic stocks. We have already wrote an background and basic knowledge report. Please see the article here: LINK.
Now it is time to act quickly and invest into the right stock
Time is money! Do you remember the massive price gains in the blockchain, cannabis or lithium sector? Almost all of these shares multiplied in the early investment period!!! Unfortunately, most investors found out about these mega-trends far too late and mostly only ran behind the parabolic price trends. In the end, some even lost small portfolio winnings, because the missed out the exit at the right time.
All of this should not happen to you here, because you will receive all information from us at first hand and will therefore be part of the new mega trend right from the beginning! Analysts certify that the psychedelics sector will be a billions market and thus investing into the right stocks will be huge for investors! We witnessed how explosively the new market is affecting prices last week in Toronto when the first stock, Mind Med, put a record IPO on the floor. The trading volume on this day was simply gigantic with over 40 million pieces traded.
We had already introduced the company to our readers in our newsletter, but consider the topic so interesting that we are now making our company analysis available to everyone else. If in the future you want to receive all information about the stock directly in your email-inbox and thus take advantage of the information at first hand, then subscribe to our free newsletter without any obligation.
Benefit from our unique network of brokers, analysts and industry experts built up over decades and subscribe now to our newsletter free of charge and without any obligation!
IPO of Mind Medicine exceeds all expectations and causes a price explosion! The company should become the BLUE CHIP in this new sector!
With the IPO of Mind Medicine Inc. (ISIN: CA60255C1095, Canada NEO: MMED) on March 03, 2020, private investors can now also participate in the upcoming new mega-pharmaceutical trend and make enormous profits as a “first mover”!
With Mind Medicine (Mind Med) we are introducing you to an extraordinarily exciting pharmaceutic psychedelic story today.
We are absolutely certain that innovative pharmaceutical companies that focus on the development of medicines based on psychedelic substances such as LSD, 18-MC (Ibogaine Derivative), MDMA and psilocybin have a bright future ahead of them. Traditional pharmaceutical companies earn billions from the manufacture of drugs to treat substance addiction (e.g. opiates), severe depression, ADHD in adults, anxiety disorders and other neurological disorders. And it is precisely these diseases, some of which are serious, that affect hundreds of millions of people worldwide that are the focus of research and development for drug candidates at Mind Med!
Business model and goals of Mind Med:
Mind Med Inc. (ISIN: CA60255C1095, Canada NEO: MMED) operates as a pharmaceutical company. The Company discovers, develops, and deploys psychedelic inspired medicines to alleviate suffering and improve health. These innovative next-generation drugs target large mega-markets, where double-digit billion dollar sales are already being generated each year.
Mind Med’s stated goal is to develop the most compelling portfolio of intellectual property (IP) and a strong clinical pipeline of drug candidates in the emerging psychedelic drug market.
One of the company’s main active ingredient, 18-MC (18-methoxycoronaridine; a non-hallucinogenic version of the psychedelic compound ibogain), purchased from Savant HWP in June 2019, has already undergone a successful Phase 1 study, and was supported with a grant of USD 6.5 million by the U.S. National Institute of Drug Abuse (NIDA). Phase 1 is the beginning of a series of studies to determine the safety and effectiveness of the medicine in humans. A phase 2 study is planned for this year, in which will have a higher number of proband involved.
The study targets opium drug addiction – an insidious epidemic that causes tens of thousands of deaths in North America each year.
At the same time, Mind Med (ISIN: CA60255C1095, Canada NEO: MMED) is preparing another clinical phase 2 study with LSD (Lysergic Acid Diethylamide) to combat Attention Deficit Hyperactivity Disorder (ADHD). Probably a promising alternative to current main medications – amphetamines (Adderall) and methylphenidate (Ritalin) – that have risks and side effects from prolonged use.
Source: Mind Med.
Disruption in the pharmaceutical sector with new treatments (by psychedelic drugs) in various neurological diseases and disorders
Mind Med is ideally positioned to attack traditional “old pharma” companies and capture market share in large blockbuster-segments such as ADHD, depression and addictions (e.g. opiates)!
Strong stock market debut (IPO) on March 03, 2020: Mind Med – a pioneer and possible future market leader among biopharmaceutical companies with a focus on psychedelic drugs!
MindMed Co-Founder and Co-CEO JR Rahn said: “Today marks a significant step forward in our ability to access further institutional capital to fund our ground-breaking clinical trials and mission to build the most compelling pipeline of psychedelic inspired medicines. NEO provided a clear, efficient path to go public on their institutional-grade main-board stock exchange. Psychedelic medicines present an opportunity to address large societal problems, like the opioid crisis, and a public listing of MindMed could help accelerate the path to a cure.”
There is no way around Mind Med! Attention: this company is a first mover in a new pharmaceutical trend sector!
Why will we all make so much money by investing in this stock, if management successfully excecute the business plan? With Mind Med (ISIN: CA60255C1095, Canada NEO: MMED) you have a real chance of a multi-bagger! Why?
Quite simply: the company’s market capitalization is currently (still) at a low C$ 106 million – and the management is planning two important clinical phase 2 studies this year alone (see above). Industry insiders see psychedelics stocks as the next hot investment theme, as it did in 2014 with cannabis stocks. The share offers high asymmetric profit potential for clever investors who invest right from the very beginning!
A professional Management team and supervisory board with guaranteed success!
We just can’t emphasize it enough, with this stock everything is just right! The company has enough money in the treasury, the project pipeline is professionally prepared and, last but not least, the company has a management with guaranteed success. The CEO JR Rahn is an excellently connected Silicon Valley specialist. He has assembled an experienced professional team (industry veterans!) with many years of experience in the research and development of pharmaceutical drugs and in the leading of clinical trials.
Star investors such as ‚Shark Tank‘ jury member Kevin O’Leary or the founder and ex-CEO of cannabis heavyweight Canopy Growth Bruce Linton would not have positioned themselves early on with Mind Med and take a board position assumed if they had not also recognized the huge potential of psychedelic substances and the promising outlook of the Mind Med stock.
Be there right from the beginning and take the chance to multiply your investment!! Time is money – don’t wait until everyone else jumps on this winning train!
Mind Med Highlights: Our buying arguments & investment case
- Mind Med is the first public listed biopharmaceutical company which focuses on psychedelic drug candidates such as MC-18 (a derivative of Ibogaine) and LSD and thus a prime go-to stock for farsighted investors.
- Clear first-mover advantage, highly successful stock market debut (IPO) on March 03, 2020 and huge demand even in the first trading days from smart investors who want to be part of the absolutely new asset class of psychedelics stocks.
- Various PRE-IPO financing rounds with over CAD 41.2 million successfully completed – the company is sufficiently financed to execute the promising business plan.
- Highly experienced management team: CEO JR Rahn is a well-connected Silicon Valley specialist. He has assembled an experienced professional team of pharma veterans with many years of experience in the research and development of clinical drugs, as well as in the leading of clinical studies.
- Strong board with prominent sector insiders: Bruce Linton, ex CEO of cannabis heavyweight Canopy Growth.
- Prominent star investors bet on Mind Med: Kevin O’Leary, who is also a jury member of the TV show ‚Shark Tank‘ and Bail’s Capital James Bailey.
- Vote of confidence: Management and insiders hold approx. 35% of the company’s shares at the IPO.
- Focused business strategy: In 2020, Mind Med is planning two important clinical phase 2 studies with 18-MC (for the treatment of opiate withdrawal symptoms) and microdose LSD for the treatment of ADHD.
- Strong patent portfolio of psychedelic drug candidates – ready for rapid development of possible blockbuster drugs with several billion USD revenue potential, after successful FDA approvals.
- Mind Mend is the first exchange-listed vehicle for early investors who want to benefit in the new mega-trend sector of psychedelics stocks right from the beginning.
- Very attractive stock at currently trading at low valuation: the share price could multiply quickly if the business plan is successfully executed.
- Mind Med holds a leadership position among exchange-traded psychedelic companies and is very likely to attract capital from investors looking for exposure to the new sub-sector.
- Pipeline expansion planned: The company plans to purchase additional drug candidates of psychedelic substances in the next 6-12 months.
- Mind Med is (in the medium term) an attractive takeover candidate by a “Big Pharma” company, who wants to get access to this new sector.
- We expext, that numerous catalysts will be released in the upcoming months – e.g. the start of two important clinical phase 2 studies, potential expansion of the IP portfolio.
- Markt Cap as of March 9, 2020: C$ 106 million
The market capitalization of just C$ 106 million is still quite low!
The stock is currently the only vehicle for investors who want to position themselves in this new pharmaceutical sector of psychedelic stocks at an early stage.
Get on board of Mind Med (ISIN: CA60255C1095, Canada NEO: MMED) right at the beginning of this new pharmaceutical trend! The majority of market participants have not heard the story as of yet – do not hesitate too long! You don’t find too many ten-bagger opportunities which potentially offer capital gains from € 5,000 to € 50,000!
|Name:||Mind Medicince (Mind Med) Inc.|
|Equity Ticker Germany:||BGHM|
|Equity Ticker Canada: (NEO)||MMED|
|Last stock price March 9, 2020:||0,445 C$|
Please note that trading volumes are generally significantly higher at the main Canadian main stock exchange (NEO) than on German stock exchanges. The stock of MindMed also trades on the Frankfurt stock exchange. We expect, that other stock exchanges such as Tradegate will also list Mind Med in the next few days. If there is enough trading volume, trades are also possible directly in Germany. Please note, however, that you always place limited orders! Limit orders are generally preferable to pure ‘buy at market’ orders.
Benefit from our unique network of brokers, analysts and industry experts built up over decades and subscribe now to our newsletter free of charge and without any obligation!
Happy reading & investing!
The contents of the „web pages“, the newsletters and other publications are prepared with the utmost care. Despite all care in the preparation, Financial Research & Publication Ltd assume no liability or responsibility for the correctness, completeness and timeliness of the information contained in the content provided. Furthermore, the relevance of any price forecasts / price targets is not guaranteed in any way whatsoever. The use of the content of the „web pages“, the newsletters and other publications is at the user’s own risk. The web offer is intended for users resident in the Federal Republic of Germany, Switzerland and Austria. The web page is not intended for users who are resident in countries other than those mentioned above, have been or are otherwise subject to the regulations of other countries. Financial Research & Publication Ltd does not assume any liability or guarantee that the information contained in this web page is in accordance with the laws of other states than the Federal Republic of Germany, Switzerland and Austria.
All publications (eg. interviews, articles, short reports, featured company reports, stock market letters, newsletters, sample portfolios, chart-technical assumptions etc.) are for information purposes only and do not constitute trade recommendations regarding the purchase or sale of the instruments discussed. All publications are not to be equated with professional financial analysis but merely reflect the opinion of the website operator (and / or its internal or external editorial staff or business partners). Our produced content has a journalistic nature. The website operator and the authors of all website content assume no responsibility for the topicality, correctness or completeness of the information contained in the publications. The website operator and the external authors are not investment advisors.
The subject of published financial analysis or website content may be shares of companies that have a low market capitalization. Especially for companies with a low market capitalization, investors often have to expect high volatility or low market liquidity.
The subject of the published content on the websites are mostly stocks, that are associated with major price risks and are therefore unsuitable for inexperienced or risk-averse investors. This is especially true for all Over The Counter (OTC), i.e. the so-called outside of a monitored stock exchange or regulated market. The same applies to shares that are traded on the Australian Stock Exchange (ASX), on Canadian stock exchanges (i.e. Toronto or Vancouver) or on the Alternative Investment Market (AIM), a segment of the London Stock Exchange. The shares we analyzed or feature at our web pages are frequently traded on any of these markets in which they are segments of the highest risk category. Instruments which are traded, are threatened at any time by the possibility of a total loss, high volatility and the possibility of reduced liquidity and marketability in particular due to low trading volumes. High price opportunities are faced with enormous risks.
All of the information contained in the „web pages“, the newsletters or other published content neither constitutes a solicitation nor an offer to sell or purchase any investment or for making other transactions. It is also not a recommendation in the context of investment advice.
Any forecasts or opinions expressed reflect our own, subjective and current views of the publisher and are for guidance and information only. The „web pages“ do not consider specific investment objectives, financial situation or particular needs of individual users. The securities and financial instruments presented on these „web pages“ may not be suitable as an investment instrument for every user. Please do your own Due Dilligence.
Financial Research & Publication Ltd assumes no liability for trade ideas, market forecasts and other information made available. This is in no way a call for individual or general reproduction. The background information, trade ideas, market forecasts and securities analyzes by Financial Research & Publication Ltd published on its „web pages“, does not constitute an offer for sale of the listings handled nor a solicitation to buy or sell shares, but also not of commodities, currencies, other securities or structured and derivative financial products. The versions are based on sources the editor believes to be trustworthy.
Although the conclusions and statements contained in the analysis, publications and market assessments have been drawn with reasonable diligence, we assume no responsibility or liability for errors, omissions or incorrect information. This is also true for all of the opinions expressed by our interlocutors in the interviews, figures and expressions. Before a customer makes investment decisions, he should have carefully gathered information about the opportunities and risks of the investment. A positive performance of a financial product in the past can in no way be an indication of a future performance. The reader is urged to check all information and allegations himself. An investment in the featured, sometimes highly speculative shares should not be made without analyzing and reading the latest balance sheets, assets reports and press releases of the company. Material on this website may contain technical or inaccuracies, typographical errors or omissions, for which we assumes no responsibility. Price forecasts for financial instruments in our stock market bulletins and newsletters do not constitute a financial analysis / investment recommendation, they are based purely on subjective technical chart based forecasts of the author.
Disclosure of Interest:
Information pursuant to Section § 34b of the German Securities Trading Act [WpHG] and to Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse (market abuse regulation)
An individual disclosure regarding securities positions of the publisher and the authors and / or the remuneration of the publisher or the authors by the company or third parties involved in publications are expressly stated in or under the respective publication. This also applies to options and derivatives based on these securities.
The website operator provides companies with marketing and advertising services. We will be compensated for advertising services by these featured companies (sponsors) or by external third parties (e.g. consultants, who have business relationship with the companies). Here is a conflict of interest. Furthermore, a consulting or other service contract may exist or existed between the featured companies promoted on our websites and Financial Research & Publication Ltd, which also constitutes a conflict of interest. Since we can at no time rule out that other media, research provider or stock promotors publish articles or feature our clients during the same period, a symmetrical generation of information and opinion can occur. Nor can it be ruled out that companies that have booked modules to increase market awareness at our websites will not use other service providers in parallel.
We are compensated by featured companies (sponsors) on our website for advertising and maketing services. We are unable to verify all of the data released by public companies or its management. Featured companies are only profiled, we do not recommend stocks to buy or sell. We cannot guarantee all information are accurate and we may make forward looking statements that are uncertain and risky.
Financial Research & Publication Ltd or employees of the Company may at any time conduct buy or sell transactions in the shares of the featured companies (i.e. long or short positions). This also applies to options and derivatives, based on these securities. Those transactions may affect the respective company’s stock price under certain circumstances. Published information on the „web pages“, the newsletters, recommendations, interviews and company presentations are often paid by the respective company or third parties (so-called „third parties“). The „third parties“ include, for example, Investor Relations, Public Relations, Consultants, Brokers and Investors. Financial Research & Publication Ltd may partly directly or indirectly be compensated for the preparation and electronic distribution and other services in cash, and/-or shares / options by the so-called „third party” or direct by featured company. Even if we create each analysis and other content to the best of knowledge and belief and professional standards, we advise you to involve further external sources, such as your local bank or a consultant you trust regarding your investment decisions.
Information and analysis provided is for entertainment, informational and educational purposes only. Nothing in an article, research report, Newsletter, stock report, commentaries interview and other published content constitutes or can be construed as investment advice or an offer or solicitation to buy or sell a stock.
Articles, interviews or other content is based on public information and conversations with Management or company employees. We are unable to verify all of the data released by public companies or its management. Featured companies are only profiled, we do not recommend stocks to buy or sell. We cannot guarantee all information are accurate and reliable. The information may not be complete or correct. We may make forward looking statements that are uncertain and risky.
We require our staff and independent external authors and clients to disclose their positions in individual securities that are mentioned in a publication that they author and that is featured on our website and written content.
IMPORTANT: Although we require our staff and independent external authors and clients to disclose their positions in individual securities that are mentioned in a publication that they author and that is featured on our websites and publications, we cannot and will not guarantee that the information they disclose or fail to disclose is accurate, honest, truthful and complete.
In addition, portions of our websites may contain opinions that are different from other portions of our websites. Our stuff, external authors, clients, advertisers and agents may, from time to time, have long and short positions in, or buy or sell the securities, or derivatives thereof, of companies mentioned in respective website or other published content and may take positions inconsistent with the views expressed in the content.
We may hire third party service providers to electronically disseminate live news and content regarding our clients / our profiled Issuers, yet we have no control over the content of and do not verify the information that the Profiled Issuers and/or third party service providers publish. These third party service providers are likely compensated for providing positive information about the Issuer even where such compensation is not disclosed by them.
No guarantee of price data
Financial Research & Publication Ltd does not assume any liability for the accuracy of the charts and data of commodities, currency and equity markets presented in the „web pages“, in the newsletters and all produced content. Displayed prices and data may be time-delayed and out-of-date.
Financial Research & Publication Ltd
20-22 Wenlock Road
London N1 7GU
E-Mail: [email protected]
Responsible person: Paul Miller
Tel. +44 20 3608 1991